Bill Gates-backed Coronavirus Vaccine Developer Skyrockets 431% Days After IPO

This German biotechnology company, has skyrocketed as much as 431% since its initial public offering on Friday…

CureVac,  is backed by Microsoft founder and billionaire Bill Gates, and is working on a potential vaccine for coronavirus. On Friday, it raised $213.3 million in its IPO, pricing at $16 per share, the high end of its expected range.

In its public trading debut, shares more than tripled, ending the day up 249% at $55.90 per share. On Monday, the biotech company’s epic rally continued as shares surged as much as 52% to reach an all-time high of $85 per share.

CureVac said in a regulatory filing that it will use the proceeds from its IPO for research and development, expanding its manufacturing capabilities, and to fund the clinical development of its potential coronavirus vaccine through the completion of its Phase 3 trial.

The company in June started its Phase 1 coronavirus vaccine trial with healthy human participants, and expects results in the fourth quarter of the year, according to the SEC filing. In addition to the coronavirus, CureVac is working…

Continue reading at BUSINESSINSIDER.com

 

 

You May Also Like

About the Author: Admin